FDA’s Special Protocol Rescissions Get U.S. Capitol, Venture Capital Attention

House Appropriations Committee wants FDA to provide more justification when it changes a special protocol assessment.

Venture capital investors want to save the shrinking value of special protocol assessments by requiring more transparency and better information flow as it pertains to rescissions.

It appears a 2013 SPA rescission may have been the tipping point for the lobbying effort, which also looks to ensure sponsors learn of potential problems related to the

More from United States

More from North America